Kura Oncology (KURA)
(Delayed Data from NSDQ)
$20.95 USD
-0.13 (-0.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
KURA 20.95 -0.13(-0.62%)
Will KURA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KURA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KURA
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
What Makes Kura Oncology (KURA) a New Buy Stock
KURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade
Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?
Other News for KURA
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
Kura Oncology appoints Vasconcelles to board of directors
Kura Oncology Welcomes New Director Michael Vasconcelles
Kura Oncology to Participate in Cantor Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Tourmaline Bio (TRML), Amicus (FOLD) and Kura Oncology (KURA)